Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ankylosing spondylitis
Pharma
Ivonescimab, Fosun-Sitala, Hutchmed—Fierce Pharma Asia
Akeso and Summit's ivonescimab bagged its first overall survival win. Fosun inked another licensing deal. Hutchmed's CEO took medical leave. And more.
Angus Liu
Aug 29, 2025 8:15am
Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial
Jul 29, 2025 8:50am
UCB collects 3 new FDA approvals for blockbuster hopeful Bimzelx
Sep 23, 2024 12:12pm
Trial win sets up AbbVie's Rinvoq up for likely Crohn's approval
May 12, 2022 9:52am
AbbVie's red-hot Rinvoq picks up 4th FDA nod in 5 months
Apr 29, 2022 5:05pm
AbbVie says Rinvoq, Skyrizi combined will outperform Humira
Jan 11, 2022 6:15pm
